Fabry disease is an X-linked recessive disorder caused by a deficiency of the lysosomal hydrolase α-galactosidase A (α-gal). The deficiency of this enzyme leads to the systemic deposition of ceramide trihexoside (CTH) in various tissues and organs. Enzyme replacement using IV doses of recombinant human α-gal produced in CHO cells or in human fibroblasts is currently being evaluated in clinical trials as a potential therapy for this disease. However, it requires lifelong therapy involving a large amount of purified α-gal. As a novel approach for treatment of Fabry disease we used polymer encapsulated Chinese hamster ovary (CHO) cells genetically modified to express α-gal. The secreted high levels of α-gal passed through the semipermeable polymeric membrane. Using coculture system with Fabry fibroblasts, the secreted enzyme was taken up in cells, resulting in reduced accumulation of CTH in Fabry fibroblasts. This in vitro study demonstrated that an encapsulated α-gal-secreting cell line can be used to treat Fabry mice by transplantation in vivo. Judging from the protection against immune rejection by a semipermeable synthetic membrane, this novel approach may be applied to treat patients with Fabry disease and other lysosomal storage diseases.
INTRODUCTION
ment therapy needs a large amount of purified α-gal for lifelong treatment, which is exceptionally costly at this Fabry disease is an X-linked recessive lysosomal time. Membrane encapsulation of tumor cell lines prestorage disorder. It is caused by a deficiency of the lysovents host rejection, allowing cross-species transplantasomal enzyme α-galactosidase A (α-gal; EC.3.2.1.22), tion without immunosuppression (1) . Several cell lines which catalyzes the degradation of glycosphingolipids have been used, such as PC 12 cells (as a catecholaminwith terminal α-galactosyl residues (5) . This defect reergic cell line) and baby hamster kidney (BHK) fibrosults in the accumulation of ceramide trihexoside (CTH), blasts, both of which were genetically modified to proespecially in the vascular endothelium. Clinical manifesduce human nerve growth factor (hNGF) (2, 13) . tations include hypohidrosis, angiokeratoma, acropares-To develop the novel treatment of Fabry disease, we thesia, and corneal opacity. Vascular diseases of the carried out in vitro experiments to find encapsulation heart, kidneys, and central nervous system develop in systems that allow free diffusion of α-gal and permit adolescence and often lead to early death (7) . long-term survival inside the capsules. The cell line em-Several therapeutic approaches have been carried out, ployed was CHO cells, which were modified by a reincluding enzyme replacement, bone marrow transplancombinant adenovirus vector to produce human α-gal. tation, and experimental gene therapy (19) . It is known
The CHO cells were encapsulated within a semipermethat the uptake of purified α-gal enzyme by Fabry fibroable polymer fiber and cocultured with the Fabry fibroblasts leads to the increase of enzyme activity in vitro blasts. α-Gal protein was secreted into the culture me- (14) . This finding suggested the possibility of enzyme dium from the capsule and reduced the amount of CTH replacement therapy for this disease. However, replacein cocultured Fabry fibroblasts in vitro. These data sug-gest that a polymer-encapsulated α-gal-secreting cell Polyacrylamide Gel Electrophoresis and Immunoblotting line could be used for the treatment of Fabry patients.
After coculture with a 6-cm capsule for 3 days, fibro-MATERIALS AND METHODS blasts were washed, harvested, and sonicated in distilled Cell Culture water containing a protease inhibitor. Aliquots of cell extracts were subjected to 12% acrylamide gel under the Human skin fibroblasts were derived from a healthy reducing condition by Laemmli's method. Protein was volunteer and two unrelated patients with Fabry disease.
visualized by using an anti-α-gal antibody and an ECL The cells were maintained in Dulbecco's modified Eagle plus Kit (Amersham, Little Chalfont, Bucks). Protein medium (DMEM) supplemented with 10% fetal bovine SDS-PAGE standards (Bio-Rad, Hercules, CA) were serum (FBS), L-glutamine, and antibiotics. CHO cells used as the molecular mass standard proteins (12). were cultured in the same medium. All experiments were tested using 4 ml of culture medium in a 6-cm Immunocytochemical Analysis dish.
After coculture with the fibroblasts and capsules for This study was approved by the Ethical Committee 3 days, the capsules were removed from the dishes and of our institution and informed consent was obtained the fibroblasts were trypsinized to prepare cell suspenfrom each subject or family.
sions. The cell suspensions were seeded on the coverslips (LAB-Tek chamber slide; Nunc, Napervile, IL) and Preparation of Capsules cultured for 2 days. CHO cells were infected with recombinant adenovi-Fibroblasts were fixed with ice-cold 2% paraformalrus vector (Ax α-gal) at mutiplicity of infection (MOI) dehyde/PBS (v/v). After blocking nonspecific binding of 30 and cultured for 2 days in DMEM supplemented with 5% goat serum and 1% bovine serum albumin in with 5% FBS as described previously (16). The cells PBS, they were treated with monoclonal mouse antiwere harvested by trypsinization and prepared in a sus-CTH IgG as a first antibody and with fluorescein isopension of 1 × 10 5 cells/µl in DMEM supplemented with thiocyanate (FITC)-conjugated Fc goat anti-mouse IgG 10% FBS.
as a second antibody (10) . The stained cells were exam-CHO cells infected with Ax α-gal recombinant adeined on a confocal fluorescence microscope system (Olymnovirus vector were encapsulated (Ax α-gal CHO cappus, Tokyo, Japan) with argon laser and filters for fluosule) as follows. Hollow fibers of polysulfone were prerescein (excitation 488 nm, emission 506 nm) (8). pared as previously described (2) (3) (4) . They exhibited RESULTS cross-sectional dimensions of 1.1 mm inner diameter and molecular cutoff was 100 kDa. Devices of 6 cm in Secretion Studies length had a septal fixture at the proximal end for cellu-
The secreted α-gal activity levels from the capsule lar loading access and were sealed at the distal end.
into the culture medium are shown in Figure 1 . The CHO cells were prepared as a single-cell suspension and α-gal activities were 22.47 ± 4.72, 5.44 ± 2.68, and infused into the septal port at a density of 1 × 10 5 cells/ 1.44 ± 0.99 (mean ± SD) nmol/h/ml on days 3, 6, and µl. After infusing 40 µl of the cellular suspension, the 9, respectively. The enzyme activity decreased and was septum was removed and the access port was sealed hardly detected on the 12th day. No α-gal activity was with a light-cured plastic. Ax α-gal CHO capsules were detected in cultured medium containing the capsule cultured in the supplemented DMEM medium and the packed with nontreated CHO cells (nontreated CHO α-gal activity in the medium was measured. capsule). CHO cells were not observed in the culture medium during the studies, indicating no leaking of Enzyme Assay those cells from the capsule. Fibroblasts were washed with a phosphate-buffered Coculture With Fibroblasts and Capsules saline solution (PBS), harvested by scraping, and then suspended in cold distilled water containing a protease Fibroblasts were harvested after 3 days from the coculture with the capsulated CHO cells, and the lyso-inhibitor (Roche, Mannheim, Germany). The suspension was sonicated and used for enzyme assay and protein somal enzyme activities were measured in the culture medium and the cell extracts (Table 1) . When Fabry or determination. Using 4-methylumbelliferyl glycosides (Sigma, St. Louis, MO) as substrates, glycosidase activi-normal fibroblasts were cultured alone, α-gal activity was not detected in the culture medium. The cell ex-ties of α-gal and N-acetyl-glucosaminidase were assayed fluorometrically (21) . Protein concentration was deter-tracts from two Fabry patients had lower α-gal activity compared with that from normal subjects. When Fabry mined by Lowry's method, using human serum albumin as a standard (12).
or normal fibroblasts were cocultured with the Ax α-gal CHO capsules, the α-gal activity increased in both the Analysis of CTH Degradation culture medium and cell extract. On the other hand, when they were cocultured with nontreated CHO cap-CTH antibody staining revealed that Fabry fibroblasts had extensive accumulation of CTH but normal sules, there was no increase in α-gal activity. N-Acetylglucosaminidase activity as a lysosomal enzyme control fibroblasts did not (Fig. 3 ). In the Fabry fibroblasts cocultured with Ax α-gal CHO capsules, the immunoreac-was not affected under these conditions. Immunoblotting analysis also indicated that the band of α-gal appeared tive fluorescence disappeared (Fig. 3C ). In the Fabry fibroblasts cocultured with nontreated control CHO cap-only in the extracts from Fabry fibroblasts (patient 2) cocultured with Ax α-gal CHO capsules (Fig. 2) . sules, the fluorescence remained ( Fig. 3B ). Values are expressed as means ± SD for three independent measurements. α-Gal activity was measured using cell extracts and culture medium of fibroblasts from Fabry patients. The cells were cultured for 3 days in the following different conditions: 
DISCUSSION
novirus vectors were transformed into the CHO cells, proliferating cells could not reproduce the transgene that Transplantation of encapsulated secretory cell lines exists in episomal nature (9) . The moderate downward has been proved to be applicable to novel types of basic curve of α-gal activity may result from this phenomenon experimentation as well as to treatment of neurodegenerand could be solved by cloning cells modified genetiative disorders such as Parkinson's disease (1) . We recally to secret α-gal. port here the efficacy of encapsulation technology appli-Our data provided the evidence that α-gal was secable to the treatment of Fabry disease.
creted into a medium from the Ax α-gal CHO capsules, We found that α-gal protein can be secreted through and this enzyme was taken up by the fibroblasts (Table  a semipermeable capsule wall as shown in the secretion 1, Fig. 2 ). Moreover, immunocytochemical analysis showed study (Fig. 1 ). In addition, several other lysosomal enthat the accumulated CTH in Fabry fibroblasts was zymes were secreted from these capsules (unpublished cleared from the cytoplasm (Fig. 3) . In our previous redata), which may indicate that these polymer-encapsuport (16), the uptake of purified α-gal occurred by endolated cell lines can be used to treat other lysosomal storcytosis through the mannose-6-phosphate receptor, reage diseases.
sulting in a decrease of accumulated glycosphingolipids. Rapid decrease of the α-gal activity could be the re-Our data suggested that degradation of accumulated sult of the CHO cells' death by encapsulation. Histologi-CTH was caused by this process. cal analysis of the capsule that was cultured for 12 days Treatment of Fabry disease has been based on α-gal showed that many CHO cells in capsule were dead but supplement therapy (11). Therapeutic approaches have some of them survived (data not shown). The 12-day been examined, such as: transplantation of kidney (17, culture capsule was cut and put back in the culture dish.
18) and bone marrow (15,22); injections of the purified CHO cells leaking from the capsule began to proliferate. enzyme (6, 20) ; and gene therapy with viral vectors Although many CHO cells inside the capsule were dead, (9, 23, 25) . the rest of the surviving CHO cells secreting α-gal might However, it is difficult to get large amounts of the have been proliferating inside the capsule. Because adepurified enzyme and the effects of injections are tempo-
